VOSI
(Voices of Safety International)

Donald C. Meserlian P.E., Chairman
264 Park Ave. N. Caldwell, NJ 07006 
dmeserlian@voicesofsafety.com 

 Tel: (973) 228-2258
Fax: (973) 228-0276
www.voicesofsafety.com


VOSI V50.3A                                                                                                       11/18/2002

STANDARD TO DELAY VACCINATING NEWBORNS

1. SCOPE

1.1 This standard delays vaccinating newborns until the Immunoglobulin E (IgE) in the umbilical cord blood is tested in order to determine whether a newborn has a compromised immune system that warrants delaying vaccination.

2. REFERENCED DOCUMENTS

2.1 Bakerman, Seymour, M.D., Ph.D. "A B C’s of Interpretive Laboratory Data", Second Edition (7th. Printing); Interpretive Laboratory Data, Inc., P.O. Box 7066, Greenville, N.C., 27835-7066; ISBN 0-945577-00=1; Copyright 1984.

2.2 VOSI Research Report 13 – V50.3A "Standard to Delay Vaccinating Newborns"

3. TERMINOLOGY

3.1 Hyper IgE - IgE in umbilical cord blood is greater than 2.00 units/ml.

    Note: Multiply conventional U/ml by 2.4 to obtain international units in mg/liter. (Ref. 2.1)

4. SIGNIFICANCE & USE

4.1 Newborns are typically given the Hepatitis B vaccine, since 1991, before leaving the hospital.

4.2 Ref. 2.1 specifies the following age dependent maximum recommended IgE:

4.3 Less adverse reactions to vaccines will occur when the immune system is strong enough to withstand the stress of vaccination.

4.4 Ref. 2.1 states the following "causes of elevation of serum IgE": parasitic infestations, allergic disorder, immunological disorders of uncertain pathogenesis, and neoplasm.

4.5 Based on the total of 1623 umbilical samples the Ref. 2.2 verifies the accuracy of the 2 U/ml established for maximum IgE.

4.6 The American Academy of Pediatrics (AAP), FDA, CDC and all other groups that recommend vaccines should reference this standard in their regulations and recommendations in accordance with the National Technology Transfer & Advancement Act of 1995 (NTTAA) and the United States National Standards Strategy which requires enforcement by the National Institute of Standards & Technology (NIST). VOSI is one of the 210 "Private Sector Standards Organizations" recognized by NIST (see www.voicesofsafety.com ...."About VOSI").

5. KEYWORDS

5.1 Hyper IgE, Immunoglobulin E, Immune System

This STANDARD is under the jurisdiction of Voices of Safety International (VOSI, www.voicesofsafety.com) committee V50 on "Public Health", and subcommittee V50.3 on "Screening Prior to Vaccination".

Copies are available from VOSI, 264 Park Ave., N. Caldwell, NJ 07006. Ph (973) 228-2258, fax (973) 228-0276